<DOC>
	<DOC>NCT01080300</DOC>
	<brief_summary>Depomed's Gabapentin Extended Release is an investigational, extended release formulation of Gabapentin that is being studied for the treatment of Hot Flashes/Hot Flushes in postmenopausal women</brief_summary>
	<brief_title>Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women</brief_title>
	<detailed_description>The primary study objective is to assess the efficacy of G-ER dosed at 1800mg daily (600mg AM, 1200mg PM), compared to placebo in reducing the average daily frequency and severity score of moderate to severe hot flashes in postmenopausal women at weeks 4 &amp; 12 of the efficacy treatment period, compared with baseline.</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Generally healthy, postmenopausal women who seek treatment for hot flashes Patients using hormone replacement therapy(HRT) must be willing to discontinue treatment Patients must be experiencing moderate to severe hot flashes Patients must be able to sign the informed consent Patients must be able to enter simple commands and complete questionnaires on the frequency and severity of their hot flashes using an electronic diary Other inclusions apply. Patients with hypersensitivity to Gabapentin Patients with severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss Patients treated with estrogen pellets or injectable progestin drug therapy within 6 months. Patients currently treated with Gabapentin or Pregabalin for any indication, including vasomotor symptoms Other exclusions apply.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Hot Flushes</keyword>
	<keyword>Vasomotor Symptoms</keyword>
	<keyword>Menopausal Hot Flashes</keyword>
</DOC>